Allergy Therapeutics (LON:AGY) Posts Earnings Results

Allergy Therapeutics (LON:AGY) announced its earnings results on Monday. The company reported GBX (0.84) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%.

Allergy Therapeutics Stock Down 3.0%

Shares of LON:AGY opened at GBX 10.09 on Wednesday. The firm has a market capitalization of £619.55 million, a PE ratio of -12.01, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. Allergy Therapeutics has a 1 year low of GBX 5 and a 1 year high of GBX 12.10. The company has a debt-to-equity ratio of 835.48, a current ratio of 1.63 and a quick ratio of 1.48. The firm’s 50-day moving average is GBX 11.27 and its two-hundred day moving average is GBX 9.52.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.